Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform Engineering

1 Sept 2005

Abstract excerpt

The aim of the present study was to produce glycosylation variants of the therapeutic Lewis Y-specific humanized IgG1 antibody IGN311 to enhance cell-killing effector function. This was achieved via genetic engineering of the glycosylation machinery of the antibody-producing host. Antibody genes were transiently cotransfected with acetyl-glycosaminyltransferase-III genes into human embryonic kidney-EBV nuclear...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Galectins and Cancer Biology
Share to Glycosylation and Glycoproteins Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16140965
DOI: 10.1158/0008-5472.can-04-4212

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform EngineeringPMID 16140965Read ↗

Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineeringSemantic proximity Read ↗

Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector functionSemantic proximity Read ↗

Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies.Semantic proximity Read ↗

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector ActivitiesSemantic proximity Read ↗

The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.Semantic proximity Read ↗

Antibody therapeutics:Semantic proximity Read ↗

Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region.Semantic proximity Read ↗

Galactosylation variations in marketed therapeutic antibodiesSemantic proximity Read ↗

Multiplexed engineering glycosyltransferase genes in CHO cells via targeted integration for producing antibodies with diverse complex-type N-glycansSemantic proximity Read ↗

Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in CancerSemantic proximity Read ↗

Combinatorial genome and protein engineering yields monoclonal antibodies with hypergalactosylation from CHO cellsSemantic proximity Read ↗

Chemoenzymatic synthesis of unusual antibody glycoforms using E. coli expressed human and bovine β-1,4-galactosyltransferase and their mutants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.